GlassScriptPhysician profile
Ashley Raye Fowler
NPI 1730388109
$4,341.75
in general payments reported to CMS, 2019-2025
35 companies · $617 in 2025
The $617 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $168 · 2021: $653 · 2022: $957 · 2023: $991 · 2024: $558 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,080 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,080.47 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,033.11 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $580.74 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $455.06 | 2019-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $314.73 | 2021-2025 | |
| Myovant Sciences INC. | $237.26 | 2021-2022 | |
| Pfizer INC. | $221.35 | 2019-2025 | |
| Organon LLC | $184.64 | 2021-2025 | Nexplanon, Jada System |
| Daiichi Sankyo INC. | $144.55 | 2019-2024 | Injectafer |
| Therapeuticsmd, INC. | $108.86 | 2019-2022 | |
| Sage Therapeutics, LLC | $88.71 | 2025 | Zurzuvae |
| Avion Pharmaceuticals | $85.86 | 2021-2023 | Balcoltra |
| Smith+Nephew, INC. | $81.94 | 2019-2022 | |
| Millicent US INC | $71.53 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Evofem Biosciences, INC. | $70.68 | 2020-2021 | |
| Mylan Pharmaceuticals INC. | $66.12 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $54.79 | 2019 | |
| Agile Therapeutics, INC. | $54.58 | 2023-2024 | Twirla |
| Hologic Sales and Service, LLC | $54.13 | 2019-2023 | Aptima, Thinprep 2000 Processor |
| Optumhealth Care Solutions, LLC | $50.95 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Exeltis, USA INC. | $49.03 | 2024-2025 | Slynd |
| Supernus Pharmaceuticals, INC. | $45.62 | 2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $38.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.73 | 2022-2024 | |
| Scynexis, INC. | $31.12 | 2022 | |
| Merck Sharp & Dohme LLC | $28.84 | 2020-2021 | |
| Lupin INC. | $22.35 | 2019-2020 | |
| Coopersurgical, INC. | $20.23 | 2024 | Paragard T 380a |
| Takeda Pharmaceuticals U.S.A., INC. | $18.96 | 2021 | |
| Kci USA, INC. | $16.06 | 2023 | Prevena |
| Teleflex LLC | $15.92 | 2025 | Quikclot |
| Gynesonics, INC. | $13.44 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Amgen INC. | $13.07 | 2024 | Evenity |
| Osiris Therapeutics INC. | $12.94 | 2019 | |
| Minerva Surgical, INC | $12.35 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Fowler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.